Novartis appoints Bertrand Bodson as Chief Digital Officer
(Thomson Reuters ONE) -
Novartis International AG /
Novartis appoints Bertrand Bodson as Chief Digital Officer
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* New leader to drive the digital transformation Novartis has embarked upon
Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief
Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the
new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO of Novartis.
He will join Novartis on January 1, 2018, and will be responsible for creating
and executing a company-wide digital strategy in close collaboration with the
Executive Committee of Novartis, working with leadership teams across the
business and external partners. Mr. Bodson will lead the digital transformation
Novartis has embarked upon to improve the way the Company uses data in drug
discovery and development, engages with patients, doctors and other
stakeholders, as well as automating business processes.
"Bertrand has a proven track record of creating and implementing successful
digital strategies across global companies, and leading cultural change in order
to make this happen at scale," said Mr. Jimenez. "This is not just about digital
helping the business. Bertrand will help us transform our business model using
digital technologies."
Mr. Bodson has extensive experience as a senior executive and entrepreneur
across a variety of industries. In his current role at Sainsbury's Argos, he has
led a highly successful transformation from a traditional catalogue business to
the third-largest online retailer in the UK.
Mr. Bodson said: "I am very excited to be joining Novartis to play a part in its
efforts to reimagine medicine by leveraging digital on behalf of millions of
patients and practitioners. While this will be one of the most important and
disruptive challenges in the years to come Novartis, as a global leader, is
particularly well positioned to drive this, and have even greater and
sustainable impact on healthcare worldwide."
He is a Belgian citizen and has lived and worked in Europe and North America.
Prior to Sainsbury's Argos he held a senior role at EMI Music and co-founded
Bragster.com, a social networking and content sharing website. Mr. Bodson also
held senior roles at online retailer Amazon, both in Seattle and across Europe.
He started his career in 1998 at Boston Consulting Group.
Mr. Bodson has an MBA from Harvard Business School in the United States and a
Masters of Commercial Engineering from the Solvay Business School/McGill
University in Belgium and Canada.
Disclaimer
This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as "to drive," "will," "to
improve," "excited," or similar terms, or by express or implied discussions
regarding potential improvements in the way Novartis uses data in drug discovery
and development, engages with patients, doctors and other stakeholders, and
automates business processes, or regarding the potential future financial impact
of such changes. You should not place undue reliance on these statements. Such
forward-looking statements are based on our current beliefs and expectations
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Novartis will improve the ways in which it uses
data in drug discovery and development, engages with patients, doctors and other
stakeholders, and automates business processes, or that any such changes will
have a positive financial impact on Novartis. In particular, our expectations
regarding such efforts and the financial performance of Novartis could be
affected by, among other things, the uncertainties inherent in digital
activities; the difficulties inherent in making large-scale changes to sizeable
organizations; the uncertainties inherent in research and development, including
clinical trial results and additional analysis of existing clinical data;
regulatory actions or delays or government regulation generally; our ability to
obtain or maintain proprietary intellectual property protection; the particular
prescribing preferences of physicians and patients; global trends toward health
care cost containment, including government, payor and general public pricing
and reimbursement pressures; general economic and industry conditions, including
the effects of the persistently weak economic and financial environment in many
countries; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
119,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Antonio Ligi
Novartis Global Media Relations
+41 61 324 1374 (direct)
+41 79 723 3681 (mobile)
antonio.ligi(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2128885/813049.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 24.08.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 557638
Anzahl Zeichen: 8263
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 307 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis appoints Bertrand Bodson as Chief Digital Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
